Live from the NIH registry
Studies recruiting near New Haven right now
Top 25 of 1,187 recruiting studies, sorted by proximity — each links to its official registry page
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Yale University — New Haven, Connecticut (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Alcohol Use Disorder, Cannabis Use Disorder
N/A
Interventional 294 participants sought
UConn Health — Farmington, Connecticut (28.6 mi)
· Sponsor: Massachusetts General Hospital
Opioid Sparing Effect of an ISP Nerve Block on Post-Op Pain Control in Posterior Cervical Spine Surgery
Pain, Postoperative
N/A
Interventional 60 participants sought
Stony Brook University Hospital — Stony Brook, New York (28.9 mi)
· Sponsor: Stony Brook University
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
PACT Kidney Care — Orange, Connecticut (5.7 mi)
· Sponsor: R1 Therapeutics
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
HNSCC, ESCC
Phase 1
Interventional 150 participants sought
Normunity Investigational Site — New Haven, Connecticut (0.3 mi)
· Sponsor: Normunity AccelCo, Inc.
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Yale University School of Medicine — New Haven, Connecticut (0.3 mi)
· Sponsor: Medtronic MiniMed, Inc.
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
Gastroesophageal Adenocarcinoma
Phase 2
Interventional 242 participants sought
Yale University — New Haven, Connecticut (0.3 mi)
· Sponsor: American Association for Cancer Research
Fear and Anxiety in Anesthesia-Naïve Patients Pre-operatively vs Post-operatively
Anxiety, Anesthesia Awareness
N/A
Observational 40 participants sought
Stony Brook University Hospital — Stony Brook, New York (28.9 mi)
· Sponsor: Stony Brook University
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Chin Augmentation
N/A
Interventional 100 participants sought
Galderma Investigational Site # 8680 — Westport, Connecticut (25.4 mi)
· Sponsor: Galderma R&D
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
Phase 3
Interventional 115 participants sought
Yale University (Adults and Pediatrics) — New Haven, Connecticut (0.3 mi)
· Sponsor: Pierre Fabre Medicament
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Generalized Myasthenia Gravis
N/A
Observational 500 participants sought
Clinical Trial Site — New Haven, Connecticut (0.3 mi)
· Sponsor: Alexion Pharmaceuticals, Inc.
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
Alcohol Withdrawal
Phase 2
Interventional 150 participants sought
The Yale Stress Center: Yale University — New Haven, Connecticut (0.3 mi)
· Sponsor: Yale University
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Phase 1
Interventional 210 participants sought
Yale Cancer Center — New Haven, Connecticut (0.3 mi)
· Sponsor: Genentech, Inc.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Phase 1
Interventional 604 participants sought
Smilow Cancer Hospital (Yale University) — New Haven, Connecticut (0.3 mi)
· Sponsor: Revolution Medicines, Inc.
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
N/A
Observational 30 participants sought
Yale School Of Medicine — New Haven, Connecticut (0.3 mi)
· Sponsor: Takeda
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut (0.3 mi)
· Sponsor: Relay Therapeutics, Inc.
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Phase 3
Interventional 882 participants sought
Nuvance Health Danbury Hospital — Danbury, Connecticut (28.1 mi)
· Sponsor: Janssen Research & Development, LLC
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Yale-New Haven Hospital — New Haven, Connecticut (0.3 mi)
· Sponsor: Eli Lilly and Company
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1
Interventional 105 participants sought
Yale Cancer Center — New Haven, Connecticut (0.3 mi)
· Sponsor: BeOne Medicines
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection Recurrence
Phase 2
Interventional 20 participants sought
Gastroenterolgy Center of Conneticut — Hamden, Connecticut (6.0 mi)
· Sponsor: Acurx Pharmaceuticals Inc.
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
Opioid Use Disorder
N/A
Interventional 10 participants sought
MRRC at The Anlyan Center — New Haven, Connecticut (0.3 mi)
· Sponsor: Yale University
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
N/A
Observational 2,000 participants sought
TG Therapeutics Investigational Trial Site — Farmington, Connecticut (28.6 mi)
· Sponsor: TG Therapeutics, Inc.
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Phase 3
Interventional 830 participants sought
Veterans Affairs Connecticut Healthcare System-West Haven Campus — West Haven, Connecticut (3.0 mi)
· Sponsor: Canadian Cancer Trials Group
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Focal Onset Seizures
Phase 2
Interventional 216 participants sought
Yale University — New Haven, Connecticut (0.3 mi)
· Sponsor: Supernus Pharmaceuticals, Inc.